Journal of Clinical Endocrinology & Metabolism, Vol 79, 780-785, Copyright © 1994 by Endocrine Society

ARTICLES

Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease

P Garnero, E Gineyts, JP Riou and PD Delmas
INSERM U-403, Hopital E. Herriot, Lyon, France.

We have used a new enzyme-linked immunoassay (ELISA) to measure the urinary excretion of type I collagen peptides (CrossLaps) released during bone matrix degradation in a sample of healthy adults comprising 146 women and 60 men, aged 31-89 yr, and in patients with metabolic bone disease. The intra- and interassay coefficients of variation were less than 10% and 13%, respectively. The recovery of CrossLaps antigen from urine samples ranged from 92-115%, and the ELISA was linear for serial sample dilutions. The CrossLaps assay does not cross-react with either free pyridinoline (Pyr) or free deoxypyridinoline (D-Pyr). CrossLaps measured by ELISA and the total excretion of Pyr measured by high performance liquid chromatography were highly correlated in normal women (n = 91; r = 0.73; P < 0.001). Urinary CrossLaps excretion increased with age in women, but not in men. In women, the menopause was reflected by a mean 141% increase in CrossLaps excretion [from an average 217 to 524 micrograms/mmol creatinine (Cr)] that was higher than the mean increase in total D-Pyr (+91%) and total Pyr (+47%) measured by HPLC and the mean increase in bone alkaline phophatase (+48%) and osteocalcin (+41%). Urinary CrossLaps excretion was increased from control values in Paget's disease (n = 32; mean, 1810 +/- 2300 micrograms/mmol Cr; P < 0.001), in patients with primary hyperparathyroidism (n = 10; mean, 780 +/- 380 micrograms/mmol Cr; P < 0.001), and in patients with hyperthyroidism (n = 27; mean, 1280 +/- 970 micrograms/mmol Cr; P < 0.001), with Z-scores (number of SD from the mean of sex- and age-matched controls) of 4.4 +/- 6.6, 1.5 +/- 1.2, and 6.7 +/- 6.5, respectively. In patients with Paget's disease, CrossLaps values were highly correlated with urinary hydroxyproline levels (r = 0.91; P < 0.001), and the decrease in urinary CrossLaps excretion was greater than that in urinary hydroxyproline (-71% vs. - 17%; P < 0.001) after 3 days of i.v. treatment with the bisphosphonate pamidronate. In patients with hyperthyroidism, CrossLaps excretion was elevated above the normal range in most patients (78%) and returned to normal within 1 month of treatment for hyperthyroidism. It is concluded that this new convenient assay represents a sensitive and specific index of the bone resorption rate, and that it should be useful for the clinical investigation and therapeutic monitoring of patients with osteoporosis and other metabolic bone diseases.

This article has been cited by other articles:

				B. Galusca, M. Zouch, N. Germain, C. Bossu, D. Frere, F. Lang, M.-H. Lafage-Proust, T. Thomas, L. Vico, and B. Estour Constitutional Thinness: Unusual Human Phenotype of Low Bone Quality J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 110 - 117. [Abstract] [Full Text] [PDF]

				D. Michalska, J. J. Stepan, B. R. Basson, and I. Pavo The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 870 - 877. [Abstract] [Full Text] [PDF]

				P. Szulc, B. Claustrat, F. Marchand, and P. D. Delmas Increased Risk of Falls and Increased Bone Resorption in Elderly Men with Partial Androgen Deficiency: The MINOS Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5240 - 5247. [Abstract] [Full Text] [PDF]

				P. Szulc, P. Garnero, B. Claustrat, F. Marchand, F. Duboeuf, and P. D. Delmas Increased Bone Resorption in Moderate Smokers with Low Body Weight: The Minos Study J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 666 - 674. [Abstract] [Full Text] [PDF]

				R. D. Chapurlat, S. K. Ewing, D. C. Bauer, and S. R. Cummings Influence of Smoking on the Antiosteoporotic Efficacy of Raloxifene J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4178 - 4182. [Abstract] [Full Text] [PDF]

				P. Alexandersen, B. J. Riis, J. A. Stakkestad, P. D. Delmas, and C. Christiansen Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 755 - 760. [Abstract] [Full Text]

				P. Szulc, F. Munoz, B. Claustrat, P. Garnero, F. Marchand, F. Duboeuf, and P. D. Delmas Bioavailable Estradiol May Be an Important Determinant of Osteoporosis in Men: The MINOS Study J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 192 - 199. [Abstract] [Full Text]

				M. Hotta, I. Fukuda, K. Sato, N. Hizuka, T. Shibasaki, and K. Takano The Relationship between Bone Turnover and Body Weight, Serum Insulin-Like Growth Factor (IGF) I, and Serum IGF-Binding Protein Levels in Patients with Anorexia Nervosa J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 200 - 206. [Abstract] [Full Text]

				N. B. Watts Clinical Utility of Biochemical Markers of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1359 - 1368. [Abstract] [Full Text] [PDF]

				J. R. Hartke Preclinical Development of Agents for the Treatment of Osteoporosis Toxicol Pathol, January 1, 1999; 27(1): 143 - 147. [Abstract] [PDF]

				C. Rosenquist, C. Fledelius, S. Christgau, B. J. Pedersen, M. Bonde, P. Qvist, and C. Christiansen Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin. Chem., November 1, 1998; 44(11): 2281 - 2289. [Abstract] [Full Text] [PDF]

				G. Pearce, D. A. Tabensky, P. D. Delmas, H. W. G. Baker, and E. Seeman Corticosteroid-Induced Bone Loss in Men J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 801 - 806. [Abstract] [Full Text]

				I. Gorai, Y. Taguchi, O. Chaki, R. K. M. Nakayama, B. C. Yang, S. Yokota, and H. Minaguchi Serum Soluble Interleukin-6 Receptor and Biochemical Markers of Bone Metabolism Show Significant Variations During the Menstrual Cycle J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 326 - 332. [Abstract] [Full Text]

				E. A. Amama, M. Taga, and H. Minaguchi The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 333 - 338. [Abstract] [Full Text]

				P. Bettica, M. Bevilacqua, T. Vago, M. Masino, E. Cucinotta, and G. Norbiato Short-Term Variations in Bone Remodeling Biochemical Markers: Cyclical Etidronate and Alendronate Effects Compared J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3034 - 3039. [Abstract] [Full Text] [PDF]